-
Abbott Laboratories Makes BMO Capital's Top Picks List
Tuesday, December 12, 2017 - 1:34pm | 454Read More...Abbott Laboratories (NYSE: ABT) had a busy 2017 after acquiring Alere and St. Jude Medical, earning the stock a nod of approval from a Wall Street analyst. The Analyst BMO Capital Markets' Joanne Wuensch upgraded Abbott's stock rating from Market Perform to Outperform with a price target...
-
Piper Jaffray Says Quidel Shares Can Continue To Rise On The Back Of New Deal With Alere
Tuesday, September 19, 2017 - 1:51pm | 340Read More...Analysts at Piper Jaffray turned bullish on Quidel Corporation (NASDAQ: QDEL), mostly due to the company's "sweetening" of its already attractive Alere Inc (NYSE: ALR) asset acquisition. The firm's William R. Quirk upgrades Quidel's stock rating from Neutral to Overweight with a price target...
-
Insiders Buy Abbott Laboratories Shares After Merger Deal Sours
Wednesday, December 21, 2016 - 4:38pm | 273Read More...Insiders at this healthcare products giant recently bought some of its shares. Those purchases followed news of a merger gone sour. The share price has drooped since those buys. Conventional wisdom says that insiders and 10 percent owners really only buy shares of a company for one...
-
Abbott Laboratories CEO Buys $15 Million In Shares
Monday, November 14, 2016 - 4:49pm | 266Read More...A global health care company CEO increased his stake after so-so earnings report. Those buys also follow headlines about a deal that may have gone sour. Insider buying often can be seen as a good sign for investors. Conventional wisdom says that insiders and 10 percent owners really only buy...
-
Here Are All The Big Biotech Mergers In 2016
Saturday, August 27, 2016 - 6:36pm | 583Read More...Biotech is one of the sectors where M&A activities never stop, as the potential for growth and development is immense. After the termination of a $160 billion merger with Allergan plc Ordinary Shares (NYSE: AGN), Pfizer Inc. (NYSE: PFE) has returned to the M&A table with a bang. Although...
-
Alere Drops After Trading Halt, JPMorgan Presentation; Recovers To Session Highs
Monday, January 11, 2016 - 1:15pm | 129Read More...Shares of Alere Inc (NYSE: ALR) were halted shortly after 10:15 AM EST on Monday ahead of the company's presentation at the JPMorgan Healthcare Conference. During Alere's presentation, the company's CEO, Namal Nawana, issued fourth quarter guidance. The company noted "unplanned...
-
Bristol-Myers and Quidel to Open Near 52-Week Highs
Thursday, October 6, 2011 - 7:37am | 500Read More...Health care companies Bristol-Myers Squibb (NYSE: BMY) and Quidel (NASDAQ: QDEL) reached new 52-week highs of $32.75 and $17.21 per share, respectively, in Wednesday's trading session. Bristol-Myers saw its price target boosted by a Bank of America/Merrill Lynch analyst yesterday on belief that...
-
UPDATE: Goldman Sachs Color on Alere PT Decrease
Thursday, June 30, 2011 - 8:28am | 161Read More...Goldman Sachs, which lowered its PT on shares of Alere (NYSE: ALR), is providing some color on the stock. “We believe the sell-off related to warfarin concerns was overdone,” Goldman Sachs writes. “We estimate that the impact of the new factor 10a's will have less than a 100 bp impact to ALR's...
-
Goldman Sachs Lowers PT On Alere To $39
Thursday, June 30, 2011 - 6:20am | 26Read More...Goldman Sachs has lowered the price target on Alere (NYSE: ALR) from $40 to $39 and maintains its Neutral rating.
-
Goldman Sachs Lowers ALR Target From $42 To $40
Thursday, April 28, 2011 - 9:29am | 27Read More...Goldman Sachs is lowering its PT on shares of Alere Inc. (NYSE: ALR) from $42 to $40. Alere currently trades at $36.51.
-
Goldman Sachs Raises ALR Target From $41 To $42
Thursday, April 14, 2011 - 7:41am | 27Read More...Goldman Sachs is raising its PT on shares of Alere Inc. (NYSE: ALR) from $41 to $42. Alere closed Wednesday at $38.88.
-
Wedbush Reports Alere Invests In Company Developing Prenatal Diagnostics
Wednesday, April 6, 2011 - 9:38am | 173Read More...According to Wedbush, Alere (NYSE: ALR) has made an investment in a company developing nucleic acid-based non-invasive prenatal diagnostics. Wedbush reported that it's unclear which company Alere invested in or the nature of the investment. “Maintaining OUTPERFORM. We remain encouraged by the...
